Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[2.]
R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Lancet, 354 (1999), pp. 1932-1939
[3.]
M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, et al.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
N Engl J Med, 340 (1999), pp. 253-259
[4.]
B. Baslund, N. Tvede, B. Danneskiold-Samsoe, P. Larsson, G. Panayi, J. Petersen, et al.
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
Arthritis Rheum, 52 (2005), pp. 2686-2692
[5.]
J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, et al.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
N Engl J Med, 350 (2004), pp. 2572-2581
[6.]
N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, et al.
Treatment of rheumatoid arthritis with humanized anti-interleukin- 6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Arthritis Rheum, 50 (2004), pp. 1761-1769
[7.]
M.C. Genovese, J.C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, et al.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med, 353 (2005), pp. 1114-1123
[8.]
S.B. Cohen, L.W. Moreland, J.J. Cush, M.W. Greenwald, S. Block, W.J. Shergy, 990145 Study Group, et al.
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Ann Rheum Dis, 63 (2004), pp. 1062-1068
[9.]
B. Mulcahy, F. Waldron-Lynch, M.F. McDermott, C. Adams, C.I. Amos, D.K. Zhu, et al.
Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.
Am J Hum Genet, 59 (1996), pp. 676-683
[10.]
P.E. Carreira, M.R. Gonzalez-Crespo, E. Ciruelo, J.L. Pablos, B. Santiago, A. Gomez-Camara, et al.
Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population.
Arthritis Rheum, 52 (2005), pp. 3015-3019
[11.]
A. Cantagrel, F. Navaux, P. Loubet-Lescoulie, F. Nourhashemi, G. Enault, M. Abbal, et al.
Interleukin-1beta, interleukin-1 receptor antagonist, interleukin- 4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis.
Arthritis Rheum, 42 (1999), pp. 1093-1100
[12.]
J.J. Gomez-Reino, J.L. Pablos, P.E. Carreira, B. Santiago, L. Serrano, J.L. Vicario, et al.
Association of rheumatoid arthritis with a functional chemokine receptor, CCR5.
Arthritis Rheum, 42 (1999), pp. 989-992
[13.]
B. Joven, N. Gonzalez, F. Aguilar, B. Santiago, M. Galindo, J. Alcami, et al.
Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis.
Arthritis Rheum, 52 (2005), pp. 354-356
[14.]
P.K. Gregersen, F. Batliwalla.
PTPN22 and rheumatoid arthritis: gratifying replication.
Arthritis Rheum, 52 (2005), pp. 1952-1955
[15.]
T. Vang, M. Congia, M.D. Macis, L. Musumeci, V. Orru, P. Zavattari, et al.
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Nat Genet, 37 (2005), pp. 1317-1319
[16.]
G.S. Firestein.
Evolving concepts of rheumatoid arthritis.
Nature, 423 (2003), pp. 356-361
[17.]
J.H. Distler, R.H. Wenger, M. Gassmann, M. Kurowska, A. Hirth, S. Gay, et al.
Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis.
Arthritis Rheum, 50 (2004), pp. 10-23
[18.]
S. Albani, B. Prakken.
T cell epitope-specific immune therapy for rheumatic diseases.
Arthritis Rheum, 54 (2006), pp. 19-25
[19.]
M. Tashiro, Y. Kawakami, R. Abe, W. Han, D. Hata, K. Sugie, et al.
Increased secretion of TNF-alpha by costimulation of mast cells via CD28 and Fc epsilon RI.
J Immunol, 158 (1997), pp. 2382-2389
[20.]
K. Gray Parkin, R.P. Stephan, R.G. Apilado, D.A. Lill-Elghanian, K.P. Lee, B. Saha, et al.
Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis.
J Immunol, 169 (2002), pp. 2292-2302
[21.]
P.P. Sfikakis, J.N. Boletis, S. Lionaki, V. Vigklis, K.G. Fragiadaki, A. Iniotaki, et al.
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
Arthritis Rheum, 52 (2005), pp. 501-513
[22.]
S. Takemura, P.A. Klimiuk, A. Braun, J.J. Goronzy, C.M. Weyand.
T cell activation in rheumatoid synovium is B cell dependent.
J Immunol, 167 (2001), pp. 4710-4718
[23.]
A. Baier, I. Meineckel, S. Gay, T. Pap.
Apoptosis in rheumatoid arthritis.
Curr Opin Rheumatol, 15 (2003), pp. 274-279
[24.]
K. Yonekawa, J.M. Harlan.
Targeting leukocyte integrins in human diseases.
J Leukoc Biol, 77 (2005), pp. 129-140
[25.]
H. Ulbrich, E.E. Eriksson, L. Lindbom.
Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease.
Trends Pharmacol Sci, 24 (2003), pp. 640-647
[26.]
S. Ribeiro, R. Horuk.
The clinical potential of chemokine receptor antagonists.
Pharmacol Ther, 107 (2005), pp. 44-58
[27.]
J.J. Haringman, M.C. Kraan, T.J.M. Smeets, K.H. Zwinderman, P.P. Tak.
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.
Ann Rheum Dis, 62 (2003), pp. 715-721
[28.]
A.E. Koch.
Chemokines and their receptors in rheumatoid arthritis: future targets?.
Arthritis Rheum, 52 (2005), pp. 710-721
[29.]
J.L. Pablos, B. Santiago, M. Galindo, C. Torres, M.T. Brehmer, F.J. Blanco, et al.
Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis.
J Immunol, 170 (2003), pp. 2147-2152
[30.]
N. Flomenberg, S.M. Devine, J.F. Dipersio, J.L. Liesveld, J.M. McCarty, S.D. Rowley, et al.
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
Blood, 106 (2005), pp. 1867-1874
[31.]
N. Ferrara, R.S. Kerbel.
Angiogenesis as a therapeutic target.
Nature, 438 (2005), pp. 967-974
[32.]
S. Tanaka, K. Nakamura, N. Takahasi, T. Suda.
Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Immunol Rev, 208 (2005), pp. 30-49
[33.]
G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam.
The protein kinase complement of the human genome.
Science, 298 (2002), pp. 1912-1934
[34.]
D. Hammaker, S. Sweeney, G.S. Firestein.
Signal transduction networks in rheumatoid arthritis.
Ann Rheum Dis, 62 (2003), pp. ii86-ii89
[35.]
M. Camps, T. Ruckle, H. Ji, V. Ardissone, F. Rintelen, J. Shaw, et al.
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Nat Med, 11 (2005), pp. 936-943
Copyright © 2006. Elsevier España S.L. Barcelona
